PCI is proud to be a founding member of the New England CRO/CMO Council. A thirty member organization that offers research, development and manufacturing capabilities across the entire continuum from drug discovery all the way through commercialization. To see all the services and capabilities the Council can offer, please go to www.necrocmo.com.
The greater Boston area is currently home to one of the world’s premier Biotech and Health Science clusters. This region is also home to the largest and most diverse CRO/CMO community serving any cluster in the US. In Boston, it is possible to outsource every aspect of a therapeutics development, from discovery services all the way through commercial manufacturing. No other life science center can boast such a wide array of technical service providers.
Right now, the Massachusetts CRO/CMO community is playing a major role in developing new pharmaceuticals across a broad range of therapeutic classes.To learn more about the MassBio CRO/CMO Committee »
The Society of Chemical Manufacturers and Affiliates (SOCMA) is dedicated to specialty chemical manufacturers, distributors and affiliated service providers. SOCMA brings more than 90 years of world-class support uniquely tailored to enhance the operational excellence of their member companies.
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.
With nearly 157,000 members, the American Chemical Society (ACS) is the world’s largest scientific society and one of the world’s leading sources of authoritative scientific information. A nonprofit organization, chartered by Congress, ACS is at the forefront of the evolving worldwide chemistry enterprise and the premier professional home for chemists, chemical engineers and related professions around the globe.
Established in 2008, North Shore InnoVentures® is a nonprofit technology business incubator committed to:
NSIV’s collaborative business model allows us to provide promising young companies office space, shared laboratories and equipment, sponsored professional services, successful entrepreneur mentors, and investor advisers. Together we help our member companies refine their business strategies, conserve capital, build strong teams, and achieve development and funding milestones.
X-ray Crystallography
Nuclear Magnetic Resonance Spectroscopy
Differential Scanning Calorimetry
Mass Spectroscopy
We started with Axel Plastics, an internal and external release agent manufacturer, since then the portfolio of products has expanded and is much more diverse, Excel from South Wales who manufacturer grey cellulose fibre, Jelu from Germany produce white cellulose fibre as well as wood plastic composite masterbatch in both soft and hard woods, PCI, one of the leading Imidazole manufacturers in the world and last but not least, A&C Catalysts, a speciality epoxy curing agent manufacturer, who has some very niche latent hardeners among other products.
Just over a decade ago Tzamal embarked on a bold and new path and therefore underwent a major reorganization. The company decided to devote almost a third of its resources to representing up and coming med-techs offering unique, innovative solutions. An intensive marketing program was introduced, specifically designed to familiarize the medical community with medical innovations. Thanks to this strategy, Tzamal is today recognized for its expertise in promoting and achieving sales for young medical technology innovators. The company is proud of its unique ability to break-down barriers and guide hospital administrators throughout replacement of obsolete medical technologies with innovative ones.
Stunning results have shown the new company succeeded in surpassing the sales peak of its predecessor within half the time. Today Tzamal enjoys annual sales of over $27 million and growing. The secret of our success lies in great part in our continuous pursue for better patient care as a main goal..Our commitment to state-of-the art health care is what drives our outstanding results.
Besides marketing existing products\companies, Tzamal is also greatly involved in development of innovative new medical technologies by mentoring and financing promising medical technology start-ups in a wide variety of fields. Via its subsidiary Tzamal Investments the company is closely guiding and financing some two dozen young companies.